Premature ovarian failure due to cyclophosphamide: A report of four cases in dermatology practice

Indian Journal of Dermatology, Venereology and Leprology

Volumn 74, Issue 2, 2008, Pages 128-132

  Saoji, Vikrant ^a  

^a NONE   (India)

Author keywords

Cyclophosphamide; Dermatology; Premature ovarian failure

Indexed keywords

ACETYLSALICYLIC ACID; ANTIOXIDANT; CYCLOPHOSPHAMIDE; NIFEDIPINE; PENTOXIFYLLINE; STEROID;

ADULT; ALLERGIC VASCULITIS; AMENORRHEA; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG WITHDRAWAL; FEMALE; FEMALE INFERTILITY; FOLLOW UP; HUMAN; HUMAN TISSUE; PEMPHIGUS; PREMATURE OVARIAN FAILURE; SCLERODERMA;

EID: 42049120729     PISSN: 03786323     EISSN: None     Source Type: Journal    
DOI: 10.4103/0378-6323.39696     Document Type: Article

References (19)

1. Pan TD, Mcdonald CJ. Cytotoxic agents. In: Wolverton SE, editor. Comprehensive dermatologic drug therapy, W.B. Saunders Company: 2001. p. 180-96.
2. Sing G, Saxena N, Agrawal A, Mishra R. Cytochrome P450 polymorphism as a predictor of ovarian toxicity to pulse cyclophosphamide in Systemic Lupus Erythematosus. J Rheumatol 2007;34:731-3.
3. Letterie GS. Anovulation in prevention of cytotoxic induced follicular attrition and ovarian failure. Hum Reprod 2004;19:831-7.
4. Boumpas DT, Austin HA 3rd, Vaughan EM, Yarboro CH, Klippel JH, Balow JE. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993;119:366-9.
5. Medeiros MM, Silverira VA, Menezes AP, Carvalho RC. Risk factor for ovarian failure in patients with Systemic Lupus Erythematosus. Braz J Med Biol Res 2001;34:1561-8.
6. Huong DL Amoura Z, Dahaut P, Sbai A, Costedoat N, Wechsler B, et al. Risk of ovarian failure and fertility after intravenous cyclophosphamide: A study of 84 patients. J Rheumatol 2002;29:2571-6.
7. Wang CL, Wang F, Bosco JJ. Ovarian failure in oral cyclophosphamide treatment for Systemic Lupus Erythematosus. Lupus 1995;4:11-4.
8. Yang XY, Zhu X, Liang LQ, Zhan ZP, Ye YJ. Risk factor of ovarian failure in patient with Systemic Lupus Erythematosus receiving cyclophosphamide therapy. Zhonghua Yi Xue Za Zhi 2005;85:960-2.
9. rd ed. Mehta Publishers: New Delhi; 2006. p. 52-90.
10. Koyama H, Wada T, Nishizawa Y, Iwanaga T, Aoki Y. Cyclophosphamide induced ovarian failure and it.s therapeutic significance in patients with breast cancer. Cancer 1977;39:1403-9.
11. Pfeifer SM, Coutifaris C. Reproductive technologies 1998: Options available for the cancer patient. Med Pediatr Oncol 1999;33:34-40.
12. Simon B, Lee SJ, Partridge AH, Runowicz CD. Preserving fertility after cancer. CA Cancer J Clin 2005;55:211-28.
13. Familiari G, Caggiati A, Nottola SA, Ermini M, Di Benedetto MR, Motta PM. Infertility: Ultrastructure of human ovarian primordial follicle after combination chemotherapy for Hodgkin's disease. Hum Reprod 1993;8:2080-7.
14. Fukutani K, Ishida H, Shinohara M, Minowada S, Niijima T, Hijikata K, et al. Suppression of spermatogenesis in patients with Behcet.s disease treated with cyclophosphamideand colchicin. Fertil Steril 1981;36:76-80.
15. Sonmezer M, Oktay K. Fertility preservation in young women undergoing breast cancer therapy. Oncologist 2006;11:422-34.
16. Somers EC, Marder W, Christman GM, Ognenovski V, McCune WJ. Use of gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe Lupus. Arthritis Rheum 2005;52:2761-7.
17. Chapman RM, Sutcliffe SB. Protection of oral contraceptive in women receiving chemotherapy for Hodgkin's disease. Blood 1981;58:849-51.
18. Whitehead E, Sholet SM, Blackledge G, Todd I, Crowther D, Beardwell CG. The effect of combination chemotherapy on ovarian function in women treated for Hodgkin's disease. Cancer 1983;52:988-93.
19. Masala A, Faedda R, Alagna S, Satt A, Chiarelli G, Rovasio PP, et al. Use of testosterone to prevent cyclophosphamide induced azoospermia. Ann Intern Med 1997;126:292-5.